Proactive monitoring vs. standard use of biologics for psoriasis
Part of Immune system & allergy, Skin clinical trials.
This study compares a proactive approach (adjusting drug levels based on regular blood tests) versus the usual way of using biologics for psoriasis. It helps see if active monitoring can improve treatment while keeping you safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of plaque psoriasis from a dermatologist.
- You've been taking secukinumab, ixekizumab, or guselkumab for at least 6 months.
- You are not taking a biologic mainly for another condition like arthritis.
- You are not on other immune-suppressing drugs (except methotrexate or acitretin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how severe your psoriasis is using skin exams, special skin imaging (dermoscopy), and quality-of-life questionnaires before and after you start a new treatment. It aims to see how well the treatment works and how it affects your daily life.
This study looks at how different ways of taking secukinumab (Cosentyx) over the long term affect skin clearance in people with moderate-to-severe psoriasis. It tries to find which dosing schedule keeps skin clear best over time.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
This study compares two biologic medications, ixekizumab and secukinumab, to see which works better for psoriasis in people aged 70 and older. Both drugs are given as injections and aim to reduce skin symptoms and improve quality of life.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study looks at skin cells at the single-cell level to predict which psoriasis treatments will work best for you. It may help doctors personalize treatment choices for plaque psoriasis.
Hear when a new Psoriasis Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.